Advertisement
The combination of Barrier Therapeutics with Stiefel Laboratories unitessome of the most exciting assets in the dermatology industry. The acquisitionof Barrier broadens Stiefel's extensive product offering with three premiumprescription products, making a wider range of treatment options available tophysicians and patients under the Stiefel umbrella. It also deepens an alreadystrong Stiefel pipeline of products by adding several promising novel productcandidates.
Advertisement
"Barrier's innovative products and pipeline are a very valuable additionto Stiefel," said Charles W. Stiefel, chairman and chief executive officer,Stiefel Laboratories. "The acquisition reinforces Stiefel's promise to providenovel, high-quality, safe and effective products for the treatment of skindiseases and our continued and enthusiastic commitment to advancing the fieldof dermatology."
In addition to bringing new assets to Stiefel, the acquisition alsoprovides the opportunity for the company to leverage its global footprint forthe newly-acquired portfolio.
"Stiefel's worldwide network includes more than 30 subsidiaries around theworld, a research and development organization spanning four continents andsix manufacturing operations," said Bill Humphries, president, StiefelLaboratories. "Combining these resources with Barrier's products will benefitmore dermatology patients around the world."
"The acquisition greatly expands the possibilities for Barrier's productsand pipeline," said Al Altomari, chief executive officer of BarrierTherapeutics. "We are excited about the contributions that can be made indermatology because of this transaction."
"The product portfolio and pipeline we have created with this acquisitionfurther solidifies Stiefel's position as the worldwide leader in dermatology,"Humphries said, "and continues to help us achieve our goal of becoming themost-respected dermatology company in the world."
The Global Headquarters of Stiefel Laboratories will remain in CoralGables, Fla., and the Marketing and Sales headquarters will remain in Duluth,Ga.
About Barrier Therapeutics
Barrier Therapeutics is a pharmaceutical company focused on thedevelopment and commercialization of products in the field of dermatology.Barrier Therapeutics currently markets three pharmaceutical products in theUnited States: Xolegel(R) (ketoconazole, USP) Gel, 2%, for seborrheicdermatitis; Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% whitepetrolatum) Ointment, for diaper dermatitis complicated by documentedcandidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution,for solar lentigines. Barrier Therapeutics has other product candidates invarious stages of clinical development for the treatment of a range ofdermatological conditions, including onychomycosis, psoriasis, acne, skinallergies, and acute fungal infections.
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories (a privately held company) is theworld's largest independent pharmaceutical company specializing indermatology. The company manufactures and markets a variety of prescriptionand non-prescription dermat
